{"url_path":"/sec/coya/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1835022/0001193125-26-218201-index.html","accession_number":"0001193125-26-218201","cik":"0001835022","ticker":"COYA","issuer_name":"Coya Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1835022/0001193125-26-218201-index.html","primary_entity_key":"0001835022","primary_entity_name":"Coya Therapeutics, Inc."},"word_count":264,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n \n\n \n\n \n\n10.1\n\n \n\n[Form of Securities Purchase Agreement, by and among the Company and purchaser signatories thereto (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on January 30, 2026).](https://www.sec.gov/Archives/edgar/data/1835022/000119312526030531/d88735dex101.htm)\n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](coya-ex31_1.htm)\n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](coya-ex31_2.htm)\n\n32.1**\n\n[Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](coya-ex32_1.htm)\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover page formatted as Inline XBRL and contained in Exhibit 101\n\n \n\n* Filed herewith.\n\n** Furnished, not filed.\n\n \n\n33\n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\nCoya Therapeutics, Inc.\n\nDate: May 12, 2026\n\nBy:\n\n/s/ Arun Swaminathan Ph.D.\n\nArun Swaminathan Ph.D.\n\nChief Executive Officer\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\n \n\nBy:\n\n/s/ David Snyder\n\n \n\n \n\n \n\nDavid Snyder\n\n \n\n \n\n \n\nChief Financial Officer and Chief Operating Officer\n\n \n\n \n\n \n\n(Principal Financial and Accounting Officer)\n\n \n\n34"}